Roche Diagnostics: Strategy development (C)
Frank Desiere, VP Strategy and Business Development, Roche Diagnostics CPS and his team including Guido Bartalena, Head of Strategy, Roche Diagnostics CPS had together created a 6 months journey called BOOST or Building our Organization’s Strategy Together of engaging 50% of the organization (through volunteer sign-ups). BOOST comprised 58 interactive workshops that ran between February and June 2018 across all CPS’s main sites and several additional locations. The workshops were facilitated by 72 senior leaders from across the organization and 803 employees took part in the sessions, both from within CPS and from other Roche Diagnostics business areas. Over 11,300 ideas were generated during the program and Bartalena’s team qualified and clustered all of them, to ensure that every contribution was considered. However Bartalena was now faced with a critical fork in the road. How was he going to incorporate these ideas into the overall strategy, and how would it be communicated back to the community?
- Building momentum based on the ideas created from the organization (and understanding the underlying risks with such an approach).
Roche Holding, Healthcare
2017 - 2018
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
The Sandoz leadership team faced an important decision as it broke away from Novartis and became a public company. Should Sandoz retain the global geographical coverage it had had in its many years as part of Novartis? Or should it focus on fewer ...
This case series explores Sandoz's spin off from Novartis, which was finalized on 4 October 2023. Case A follows Richard Saynor's (CEO, Sandoz) ruminations as he builds the company strategy in preparation for the board's approval of Sandoz as a st...
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-2669 ©2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD Brain Circuits 4 September 2025
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD Brain Circuits 26 August 2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications